Analyze the Treatment Protocols for Choriocarcinoma Focusing on Chemotherapy Regimens and Their Outcome
DOI:
https://doi.org/10.70749/ijbr.v3i5.2587Keywords:
Outcome, choriocarcinoma, chemotherapy,Abstract
Background: The most prevalent type of gestational trophoblastic neoplasia that medical oncologists see is choriocarcinoma. It is an uncommon ailment, and there is little information available about its long-term effects from Pakistan. Objective: The main goal of this study was to evaluate the clinical outcomes and clinicopathological features of patients with choriocarcinoma. The secondary goal was to evaluate the relationship between outcomes and risk classification. Materials and Methods: The People's University of Medical and Health Sciences for Women, Shaheed Benazirabad, Sindh, served as the site of this single-center study. The study included all individuals between the ages of 18 and 70 who had been diagnosed with choriocarcinoma, either by histological diagnosis, serum beta human chorionic gonadotropin [HCG] levels, radiological image, or a combination of clinical characteristics. Patients who did not receive treatment but merely came to the hospital for an opinion were not included. We next took note of the patients' baseline features, treatment information, and clinical results. Baseline variables were analyzed using descriptive statistics, and the survival analysis was conducted using the Kaplan–Meier technique. Results: The study had a total of 24 patients. The patients were 29 years old on average. Eight individuals had low WHO risk scores (33.3%), while sixteen patients had high WHO risk scores (66.7%). Six patients (25 percent) received single-agent chemotherapy, 14 patients (66.7 percent) received the EMA-CO regimen (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine), and one patient (4.7 percent) received the VIP regimen (etoposide, ifosfamide, and cisplatin). Only high-risk patients were administered the latter two regimens. Conclusion: In conclusion, our research supports the notion that choriocarcinoma is a very curable disease and offers real-world evidence for this uncommon cancer. The long-term results are positive in spite of the clinicopathological differences across the nation.
Downloads
References
1. Brinton LA, Bracken MB, Connelly RR. Choriocarcinoma incidence in the United States Am J Epidemiol. 1986;123:1094–100
https://doi.org/10.1093/oxfordjournals.aje.a114337
2. Smith HO, Qualls CR, Prairie BA, Padilla LA, Rayburn WF, Key CR. Trends in gestational choriocarcinoma: A 27-year perspective Obstet Gynecol. 2003;102:978–87
https://doi.org/10.1097/00006250-200311000-00017
3. Ngan HY, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al Update on the diagnosis and management of gestational trophoblastic disease Int J Gynaecol Obstet. 2018;143(Suppl 2):79–85.
https://doi.org/10.1002/ijgo.12615
4. Latif MF, Azam F, Tirmazy SHH, Bukhari N. Treatment outcomes of Gestational trophoblastic disease, Experience from Saudi Arabia. J Ayub Med Coll Abbottabad 2024;36(2):289–93.
https://doi.org/10.55519/jamc-02-12695
5. Hussain SS, Raees M, Rahim R. Ten-Year Review of Gestational Trophoblastic Disease at Lady Reading Hospital, Peshawar. Cureus 2022;14(7):e26620.
https://doi.org/10.7759/cureus.26620
6. Lawrie TA, Alazzam M, Tidy J, Hancock BW, Osborne R. First-line chemotherapy in low-risk gestational trophoblastic neoplasia Cochrane Database Syst Rev 2016. 2016 CD007102
https://doi.org/10.1002/14651858.cd007102.pub3
7. Alazzam M, Tidy J, Osborne R, Coleman R, Hancock BW, Lawrie TA. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia Cochrane Database Syst Rev 2016. 2016 CD008891
https://doi.org/10.1002/14651858.cd008891.pub2
8. Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJ, et al EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients J Clin Oncol. 1997;15:2636–43
https://doi.org/10.1200/jco.1997.15.7.2636
9. Bafna UD, Ahuja VK, Umadevi K, Srinivasan N, Mani K, Vallikad E. Gestational trophoblastic tumors – Situation analysis in a third world regional cancer center Int J Gynecol Cancer. 1997;7:197–204
https://doi.org/10.1046/j.1525-1438.1997.00441.x
10. Gulia S, Bajpai J, Gupta S, Maheshwari A, Deodhar K, Kerkar RA, et al Outcome of gestational trophoblastic neoplasia: Experience from a tertiary cancer centre in India Clin Oncol (R Coll Radiol). 2014;26:39–44
https://doi.org/10.1016/j.clon.2013.08.010
11. Hussain A, Aziz SA, Bhatt GM, Lone AR, Hussain HI, Wani B, et al Gestational trophoblastic neoplasia: Experience from a tertiary care center of India J Obstet Gynaecol India. 2016;66:404–8.
https://doi.org/10.1007/s13224-015-0710-0
12. Nzayisenga I, Segal R, Pritchett N, Xu MJ, Park PH, Mpanumusingo EV, et al Gestational trophoblastic neoplasia treatment at the Butaro Cancer Center of excellence in Rwanda J Glob Oncol. 2016;2:365–74
https://doi.org/10.1200/jgo.2015.002568
13. May T, Goldstein DP, Berkowitz RS. Current chemotherapeutic management of patients with gestational trophoblastic neoplasia Chemother Res Pract 2011. 2011 806256
https://doi.org/10.1155/2011/806256
14. Shrivastava S, Kataki AC, Barmon D, Deka P, Bhuyan C, Bhargav SJ. Gestational trophoblastic neoplasia: A 6 year retrospective study South Asian J Cancer. 2014;3:33–7.
https://doi.org/10.4103/2278-330x.126516
15. Suprasert P, Siriaree S, Manopunya M. Outcomes of Metastatic Gestational Trophoblastic Neoplasia: Fourteen Year Experience from a Northern Thailand Tertiary Care Center. Asian Pac J Cancer Prev. 2016;17(3):1357-62.
https://doi.org/10.7314/apjcp.2016.17.3.1357
16. You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, et al Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements Br J Cancer. 2013;108:1810–6.
https://doi.org/10.1038/bjc.2013.123
17. Jiang F, Yang Y, Ji ML, Yang JJ, Zhao J, Ren T, Feng FZ, Wan XR, Xiang Y. [Clinical outcome of patients with gestational trophoblastic neoplasia receiving primary treatment at Peking Union Medical College Hospital: a 30 year retrospective cohort study]. Zhonghua Fu Chan Ke Za Zhi. 2018;53(6):364-370.
18. Li L, Wan X, Feng F, Ren T, Yang J, Zhao J, Jiang F, Xiang Y. Pulse actinomycin D as first-line treatment of low-risk post molar non-choriocarcinoma gestational trophoblastic neoplasia. BMC cancer. 2018;18(1):585.
https://doi.org/10.1186/s12885-018-4512-5
19. Chapman-Davis E, Hoekstra AV, Rademaker AW, Schink JC, Lurain JR. Treatment of nonmetastatic and metastatic low risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. Gynecol Oncol. 2012;125(3):572-75.
https://doi.org/10.1016/j.ygyno.2012.03.039
20. Kim GS, Hwang KA, Choi KC. A promising therapeutic strategy for metastatic gestational trophoblastic disease: Engineered anticancer gene-expressing stem cells to selectively target choriocarcinoma Oncol Lett. 2019;17:2576–82.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
